Laboratory tests, adipokines, and cytokines in Takayasu arteritis (TA) patients with and without metabolic syndrome (MetS) according to International Diabetes Federation/American Heart Association criteria.
| TA Patients with MetS, n = 15 | TA Patients without MetS, n = 30 | p | |
|---|---|---|---|
| Glucose, mg/dl | 97.94 ± 38.13 | 81.30 ± 8.52 | 0.026 |
| Total cholesterol, mg/dl | 207.93 ± 48.90 | 179.94 ± 40.55 | 0.041 |
| LDL-C, mg/dl | 131.93 ± 45.12 | 103.74 ± 36.26 | 0.028 |
| HDL-C, mg/dl | 43.94 ± 10.06 | 60.60 ± 15.17 | < 0.001 |
| TG, mg/dl | 162.47 ± 64.78 | 77.37 ± 39.76 | < 0.001 |
| Insulin, mU/ml | 16.26 ± 0.51 | 7.40 ± 4.89 | < 0.001 |
| HOMA-IR | 4.28 ± 3.76 | 1.48 ± 1.04 | 0.568 |
| HOMA-IR > 3.4, n | 7 (46.67) | 2 (6.67) | 0.002 |
| apoA1, mg/dl | 140.62 ± 25.95 | 148.72 ± 30.28 | 0.381 |
| apoA2, mg/dl | 32.89 ± 4.89 | 34.97 ± 20.03 | 0.839 |
| apoB, mg/dl | 104.93 ± 37.12 | 74.96 ± 25.38 | 0.003 |
| apoE, mg/dl | 5.06 ± 1.82 | 4.32 ± 1.04 | 0.089 |
| Lipoprotein A, mg/dl | 58.80 ± 76.12 | 50.00 ± 67.97 | 0.697 |
| CRP, mg/dl | 10.94 ± 12.74 | 9.34 ± 11.34 | 0.671 |
| ESR, mm | 16.14 ± 9.15 | 19.27 ± 18.37 | 0.537 |
| Creatinine, mg/dl | 0.75 ± 0.15 | 0.78 ± 0.17 | 0.565 |
| Adiponectin, μg/ml | 20.37 ± 21.16 | 38.64 ± 22.62 | 0.022 |
| Resistin, ng/ml | 18.98 ± 9.11 | 24.08 ± 13.72 | 0.246 |
| PAI-1, ng/ml | 56.48 ± 20.19 | 49.68 ± 25.25 | 0.415 |
| IL-12, pg/ml | 2.27 ± 1.85 | 5.08 ± 11.03 | 0.892 |
| IL-1α, pg/ml | 6.23 ± 7.87 | 8.38 ± 12.56 | 0.847 |
| IL-6, pg/ml | 1.38 ± 2.01 | 3.25 ± 5.88 | 0.834 |
| TNF-α, pg/ml | 5.62 ± 2.65 | 7.23 ± 4.89 | 0.264 |
Data are mean ± SD or percentages. LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; HOMA-IR: homeostatic model assessment of insulin resistance; apo: apolipoprotein; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; PAI-1: plasminogen activator inhibitor-1; IL: interleukin; TNF-α: tumor necrosis factor-α; TG: triglycerides.